Fasenra 30 mg solution for injection in pre-filled pen *

  • Company:

    AstraZeneca Pharmaceuticals (Ireland) DAC
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    This medicinal product is subject to additional monitoring.

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 July 2021

File name

20210708 SPC IE MT Fasenra PFS and PFP MELTEMI Update RSP 21 0008_1626348519.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 31 March 2021

File name

20210326 Package Leaflet IE MT Fasenra PFP 30 mg Nijmegen Change RSP 21 0004_1617204157.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

EDM Updated on 21 April 2020

File name

20190627-uim-ifu-Fasenra-AI only-RSP 19 0041_1587458441.pdf

Reasons for updating

  • Add New Doc

Updated on 21 April 2020

File name

20190627-uim-spc-Fasenra-PFS SA and AI-RSP 19 0039_1587458295.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 21 April 2020

File name

20190627-uim-pl-Fasenra-AI only-RSP 19 0038_1587458049.pdf

Reasons for updating

  • New PIL for new product